Depreciation in USD of Ambrx Biopharma Cayman, Inc. from 2021 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Ambrx Biopharma Cayman, Inc. quarterly/annual Depreciation history and change rate from 2021 to Q2 2023.
  • Ambrx Biopharma Cayman, Inc. Depreciation for the quarter ending 30 Jun 2023 was $200,000.000, unchanged year-over-year.
  • Ambrx Biopharma Cayman, Inc. annual Depreciation for 2022 was $800,000.000, a 33.3% increase from 2021.
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Change (%)
Depreciation, Annual (USD)
Depreciation, YoY Annual Change (%)

Ambrx Biopharma Cayman, Inc. Quarterly Depreciation (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 $200,000 $0 0% 01 Apr 2023 30 Jun 2023 10-Q 09 Aug 2023
Q2 2022 $200,000 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023

Ambrx Biopharma Cayman, Inc. Annual Depreciation (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2022 $800,000 +$200,000 +33.3% 01 Jan 2022 31 Dec 2022 10-K 30 Mar 2023
2021 $600,000 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023
* An asterisk sign (*) next to the value indicates that the value is likely invalid.